On April 17, 2025, Tempus AI, Inc. entered agreements with AstraZeneca and Pathos AI for developing a large multimodal oncology model, involving $35 million from AstraZeneca and $200 million in data license fees over three years. This collaborative project emphasizes Tempus's pivotal role in advancing oncology through innovative data usage.